Notice type: 3rd Party Publications
Problem Or Issue:
Important Safety Information from Novartis Ireland Ltd regarding ADAKVEO (crizanlizumab): revocation of EU marketing authorisation due to lack of therapeutic efficacy
Important Safety Information – ADAKVEO (crizanlizumab)